Education
About Us
Working with TipRanks
Follow Us
Zelira Therapeutics (AU:ZLD)
ASX:ZLD
RESEARCH TOOLSreports
See the Price Targets and Ratings of:
ZLD Financial Forecast
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
AU$0.5
Sell
19.05%
Upside
Downgraded
07/05/25
Zelira Therapeutics has a low overall stock score primarily due to its poor financial performance indicated by persistent losses, negative equity, and cash flow inefficiencies. Technical analysis suggests continued bearish momentum, and the valuation is unattractive due to the lack of profitability.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
AU$0.5
Sell
19.05%
Upside
Downgraded
07/05/25
Zelira Therapeutics has a low overall stock score primarily due to its poor financial performance indicated by persistent losses, negative equity, and cash flow inefficiencies. Technical analysis suggests continued bearish momentum, and the valuation is unattractive due to the lack of profitability.
ZLD Analyst Recommendation Trends
Rating
May 25
Jun 25
Strong Buy
0
0
Buy
0
0
Hold
1
3
Sell
0
1
Strong Sell
0
0
total
1
4
Each month's total comprises the sum of three months' worth of ratings.
ZLD Stock Forecast FAQ
What is AU:ZLD’s average 12-month price target, according to analysts?
Based on analyst ratings, Zelira Therapeutics’s 12-month average price target is 0.50.
What is AU:ZLD’s upside potential, based on the analysts’ average price target?
Zelira Therapeutics has 19.45% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Zelira Therapeutics a Buy, Sell or Hold?
Zelira Therapeutics has a consensus rating of Hold, which is based on 0 buy ratings, 0 hold ratings and 0 sell ratings.
What is Zelira Therapeutics’s share price target?
The average share price target for Zelira Therapeutics is 0.50. This is based on 0 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is AU$0.50 ,and the lowest forecast is AU$0.50. The average share price target represents 19.45% Increase from the current price of AU$0.42.
The highest analyst share price target is AU$0.50 ,and the lowest forecast is AU$0.50. The average share price target represents 19.45% Increase from the current price of AU$0.42.
What do analysts say about Zelira Therapeutics?
Zelira Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 0 Wall Streets Analysts.
How can I buy shares of Zelira Therapeutics?
To buy shares of AU:ZLD, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.